US FDA asks for more info on J&J's Doribax
This article was originally published in Scrip
Executive Summary
The US FDAhas told Johnson & Johnsonthat it will require additional information before approving the intravenous antibiotic Doribax (doripenem) for the additional use of treating hospital-acquired pneumonia, including ventilator-associated pneumonia (VAP).